Non–Small Cell Lung Cancer Coverage from Every Angle

Martin Reck, MD, PhD, on Dual Immunotherapy Plus Chemotherapy: A Better Way to Treat NSCLC Than Chemotherapy Alone?

Posted: Tuesday, June 22, 2021

Martin Reck, MD, PhD, of LungenClinic, discusses the clinical implications of phase III findings from the CheckMate 9LA trial, which showed that first-line nivolumab plus ipilimumab plus chemotherapy demonstrated more durable survival and benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.